When used as adjuvant endocrine therapy in breast cancer, tamoxifen works best against larger, less aggressive, PR–positive tumours, according to results from a long term follow up study. In postmenopausal women with lymph node–negative, ER-positive/ERBB2-negative breast the markers most significantly associated with long-term survival were tumour size followed by tumour grade and progesterone receptor–positive status, ...
Breast cancer markers of long term survival and tamoxifen benefit identified in 25 year study
By Michael Woodhead
6 Jul 2021